查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1950451

D-α-对羟基苯基甘氨酸甲酯市场按来源、生产工艺、剂型、纯度等级、应用和最终用途行业划分，全球预测，2026-2032年

D Alpha Parahydroxy Phenylglycine Methyl Ester Market by Source, Production Process, Form, Purity Grade, Application, End Use Industry - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年 D-α-对羟基苯基甘胺酸甲酯市值为 4,068 万美元，预计到 2026 年将成长至 4,366 万美元，复合年增长率为 8.57%，到 2032 年将达到 7,237 万美元。

关键市场统计数据
基准年 2025 4068万美元
预计年份：2026年 4366万美元
预测年份 2032 7237万美元
复合年增长率 (%) 8.57%

本文全面观点了该化合物的理化性质、工业重要性以及其在生命科学价值链中不断演变的供应链角色。

D-α-对羟基苯基甘氨酸甲酯在先进合成化学和生物催化製程设计的交叉领域占据战略地位，可作为多种生物活性分子的掌性结构单元。其分子特性——掌性、对羟基取代基和酯基官能基——使其在建构抗生素骨架和某些酶抑制剂结构的立体选择性合成中具有特殊价值。近年来，化学品製造、药物研发和特种原料供应链中的相关人员越来越重视这种中间体，不仅将其视为一种大宗商品，更将其视为一种性能差异化因素，其来源、纯度和生产路线对下游收率、监管风险和製剂稳定性均有显着影响。

对重塑生产、监管和技术采用的融合动态的分析，正在重新定义供应商和用户的竞争优势。

在永续性优先事项、触媒技术进步以及建立韧性供应链的推动下，D-α-对羟基苯基甘胺酸甲酯的市场环境正经历变革性变化。绿色化学的迫切需求正在加速对酵素途径和发酵平台的投资，与传统化学合成相比，这些途径和平台能够减少有害试剂的使用和能源消耗。随着催化剂选择性和下游纯化技术的改进，越来越多的製造商正在探索将生物催化的立体选择性与化学製程的扩充性的混合生产流程。这种混合方法有助于降低杂质含量，并提高高纯度产品的批次间性能一致性。

对近期美国关税政策变化对采购、供应商策略、合约架构和营运应对措施的累积影响进行重点评估

美国2025年实施的关税政策对整个掌性中间体供应链产生了具体而多样的影响，进而影响了筹资策略和营运重点。关税差异加大了本地采购的奖励，一些公司加快了邻近地区替代供应商的资格认证，以降低到岸成本波动和前置作业时间风险。这种转变促使企业更加重视尽可能进行垂直整合。拥有原料药原料药和製剂生产能力的公司正在考虑后向整合，以保护其业务免受关税造成的利润率下降的影响。

详细的細項分析揭示了应用、产业、来源、製造流程、形态和纯度等方面的差异如何影响采购、品质和研发重点。

中间体的细分市场趋势表明，在应用、终端用户产业、来源、生产流程、剂型和纯度等方面，存在着不同的驱动因素和权衡取舍，这些因素都会影响供应商和买家的行为。依应用领域划分，需求主要由抗生素中间体和酵素抑制剂驱动，其中抗生素中间体可细分为头孢菌素和青霉素类分子。立体化学完整性和杂质控制对这些分子至关重要。在终端用户产业，这些化合物供应给农业化学品配方商、个人护理成分开发商和製药公司。製药领域又可进一步细分为原料药生产和製剂，两者对杂质谱和包装形式的接受度各不相同。

区域策略概述重点介绍各主要区域在采购重点、监理要求及产能投资上的差异

区域趋势表明，各主要区域的策略重点和风险状况存在差异，这对供应商如何定位自身能力以及买家如何确定采购优先顺序产生了重大影响。在美洲，商业性和监管趋势倾向于近岸外包和一体化供应链网络，以降低运输风险并简化监管申报流程，尤其对于专注于原料药生产和药品製剂的製造商而言更是如此。对扩大本地生产能力和品质系统的投资体现了对供应安全和快速反应不断变化的临床和商业需求的重视。

能够创造供应商优势的组织策略和能力差异化因素，包括整合、分析、伙伴关係和品质领导。

该领域的主要企业展现出清晰的策略模式，将技术差异化、品质保证和商业性灵活性融为一体。一些企业专注于深度垂直整合，将原料生产与下游原料药製造和製剂生产活动紧密结合，以保障利润率并控制关键品质属性。另一些企业则优先考虑专业化、高纯度生产和高端定位。先进分析技术（例如掌性纯度评估和杂质分析）的投资是通用的能力差异化因素，能够加快客户合格并降低批次不合格的风险。

为降低供应风险、加速流程创新以及使商业环境适应不断变化的贸易和监管压力，提出切实可行的跨行业建议

产业领导者应采取多管齐下的策略来降低供应风险、提高製程效率并加强客户关係。首先，他们应建立多元化的供应商组合，涵盖不同的来源和地区，从而降低贸易政策变化带来的风险，并积极寻找能够提供互补生产路线（例如发酵和合成技术）的供应商。其次，他们应投资于生物催化剂的研发和混合製程的实施，以实现更高的立体选择性并降低下游纯化负担，从而提高总收率和杂质控制。这些投资应与增强的分析能力相结合，以便快速评估掌性纯度并检测微量污染物。

本执行摘要的调查方法采用混合方法，结合专家访谈、技术文献综合、监管审查和情境检验，以得出可靠的结论。

本执行摘要的研究结合了对相关领域专家的定性访谈和对已发表的技术文献、监管指南以及专利概况的二手研究，以确保证据基础的充分性和平衡性。一级资讯来源包括对製程化学家、品管经理、采购主管和生物催化专家的结构化访谈，从而获得关于生产路线选择、认证时间表和纯度要求等方面权衡取舍的第一手资料。二级资讯来源用于分析生产技术、监管预期和区域贸易模式，这些资料的选择是基于其技术严谨性和与合成及纯度控制的相关性。

一份全面分析报告，概述了生产路线选择、供应弹性、品管和商业化路径的策略要务。

总之，D-α-对羟基苯基甘氨酸甲酯是一种具有重要策略意义的中间体，其生产路线、纯度等级和地理来源对下游开发和商业性成果有显着影响。新的市场格局优先考虑製程创新（尤其是生物催化和混合製程），以及更严格的分析控制和可记录的供应链透明度。关税趋势提高了供应商多元化和合约柔软性的溢价，推动了对区域产能和工艺优化的投资，以降低到岸成本波动和前置作业时间延长的风险。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. D-α-对羟基苯基甘氨酸甲酯市场（按来源划分）

  • 发酵法
  • 合成

9. 依生产製程分類的D-α-对羟基苯基甘氨酸甲酯市场

  • 生物催化剂
  • 化学合成

10. D-α-对羟基苯基甘氨酸甲酯市场（按形式划分）

  • 液体
  • 粉末

11. D-α-对羟基苯基甘氨酸甲酯市场（依纯度等级划分）

  • 高纯度
  • 标准产品
  • 超高纯度

第十二章 D-α-对羟基苯基甘氨酸甲酯市场按应用领域划分

  • 抗生素中间体
    • 头孢菌素
    • 青霉素
  • 酵素抑制剂

13. D-α-对羟基苯基甘氨酸甲酯市场（按最终用途行业划分）

  • 杀虫剂
  • 个人护理
  • 製药
    • API生产
    • 配方

14. D-α-对羟基苯基甘氨酸甲酯市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 D-α-对羟基苯基甘氨酸甲酯市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国D-α-对羟基苯基甘氨酸甲酯市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

17. 美国D-α-对羟基苯基甘氨酸甲酯市场

18. 中国D-α-对羟基苯基甘氨酸甲酯市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Ajinomoto Co., Inc.
  • Amino GmbH
  • BASF SE
  • Cambrex Corporation
  • Daicel Corporation
  • Evonik Industries AG
  • Hubei Xingfa Pharmaceuticals（Group）Co., Ltd
  • Jiangsu Feiyue Pharmaceutical Co., Ltd.
  • Jubilant Life Sciences Limited
  • Lonza Group AG
  • Mitsubishi Chemical Group Corporation
  • Piramal Pharma Limited
  • Shandong Lukang Pharmaceutical Co., Ltd.
  • Shandong Xinhua Pharmaceutical Co., Ltd.
  • Sichuan Guoguang Agrochemical Co., Ltd.
  • Sichuan Tongsheng Amino Acid Co., Ltd.
  • Sumitomo Chemical Co., Ltd.
  • Taizhou Yuandong Biotechnology Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd
  • Wuxi Jinghai Amino Acid Co., Ltd.
  • Zhejiang Kaili Industrial Group Co., Ltd.
  • Zhejiang NHU Co., Ltd
Product Code: MRR-4F7A6D4FD871

The D Alpha Parahydroxy Phenylglycine Methyl Ester Market was valued at USD 40.68 million in 2025 and is projected to grow to USD 43.66 million in 2026, with a CAGR of 8.57%, reaching USD 72.37 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 40.68 million
Estimated Year [2026] USD 43.66 million
Forecast Year [2032] USD 72.37 million
CAGR (%) 8.57%

Comprehensive introductory perspective on the compound's physicochemical attributes, industry relevance, and evolving supply chain role across life sciences value chains

D-Alpha Parahydroxy Phenylglycine Methyl Ester occupies a strategic position at the intersection of advanced synthetic chemistry and biocatalytic process design, serving as a chiral building block for a range of biologically active molecules. Its molecular attributes-chirality, para-hydroxy substitution, and ester functionality-make it particularly valuable for stereoselective syntheses that underpin antibiotic scaffolds and select enzyme inhibitor architectures. Over recent years, stakeholders across chemical manufacturing, pharmaceutical development, and specialty ingredient supply chains have increasingly treated this intermediate not as a commodity but as a performance differentiator whose provenance, purity, and production route materially affect downstream yield, regulatory risk, and formulation stability.

As environmental and regulatory pressures mount, the choice between fermentation-derived and synthetically produced material has taken on added significance. Process decisions influence not only cost and lead time but also trace impurity profiles and carbon intensity footprints, which in turn shape purchasing strategies among API manufacturers and formulators. Concurrently, the shift toward sophisticated purity grades-spanning standard to ultra pure-reflects heightened expectations from both R&D chemists and quality assurance teams. In this context, the compound's role extends beyond a mere reagent: it is a lever for quality, compliance, and competitive differentiation across the pharmaceutical, agrochemical, and personal care value chains.

Analysis of converging forces reshaping production, regulatory scrutiny, and technological adoption that are redefining competitive advantage for suppliers and users

The landscape for D-Alpha Parahydroxy Phenylglycine Methyl Ester is undergoing transformative shifts driven by sustainability priorities, technological advances in biocatalysis, and the push for resilient supply chains. Green chemistry imperatives are accelerating investment in enzymatic routes and fermentation platforms that reduce hazardous reagents and energy intensity relative to traditional chemical synthesis. As catalytic selectivity and downstream purification technologies improve, more manufacturers are evaluating hybrid production flows that combine the stereo-specificity of biocatalysis with the scalability of chemical steps. This hybrid approach reduces impurity burden and often yields more consistent lot-to-lot performance for high-purity grades.

At the same time, digitalization of manufacturing operations-through advanced process control, real-time analytics, and predictive maintenance-enables tighter control over critical quality attributes. These capabilities shorten development cycles and de-risk scale-up, making it feasible for new entrants to compete on the basis of quality and responsiveness rather than only on cost. Regulatory evolution toward greater scrutiny of supply chain transparency and impurity profiling has prompted closer collaboration between suppliers and end users, with longer qualification horizons and supplier audits becoming common practice. Taken together, these shifts are reshaping procurement criteria and elevating process innovation as a central axis of competitive advantage.

Focused assessment of the cumulative effects of recent US tariff policy changes on sourcing, supplier strategies, contractual frameworks, and operational responses

United States tariff measures introduced in 2025 have produced tangible but varied effects across the supply chain for this chiral intermediate, influencing sourcing strategies and operational priorities. Tariff differentials have increased incentives for regional sourcing, prompting some firms to accelerate qualification of alternative suppliers in proximate jurisdictions to mitigate landed cost volatility and lead-time risk. This reorientation has been accompanied by a heightened emphasis on vertical integration where possible: firms with downstream API or formulation capabilities have examined backward integration to insulate operations from tariff-driven margin erosion.

At the same time, tariff impacts extend beyond direct cost adjustments; they alter negotiation dynamics and contract structures. Longer-term procurement agreements now more commonly include clauses addressing tariff pass-through, force majeure that references trade policy changes, and flexible delivery terms to manage inventory buildup. The tariff environment has also encouraged investment in process optimization and yield improvement to offset increased import burdens, while manufacturers with scale and diverse production footprints emphasize adaptive capacity that allows shifting volume between synthetic and fermentation routes. Ultimately, the combined effect of tariffs in 2025 is to strengthen the premium on supply chain agility, supplier diversification, and close alignment between procurement, operations, and regulatory affairs.

In-depth segmentation insights revealing how application, industry, source, process, form, and purity distinctions drive procurement, quality, and R&D priorities

Segment-level dynamics for this intermediate reveal differentiated drivers and trade-offs across application, end-use industry, source, production process, form, and purity, each shaping supplier and buyer behavior. Based on application, demand stems primarily from antibiotic intermediates and enzyme inhibitors, with antibiotic intermediates further subdivided into cephalosporin class and penicillin class molecules where stereochemical integrity and impurity control are paramount. Within end-use industries, the compound serves agrochemical formulators, personal care ingredient developers, and pharmaceuticals; the pharmaceutical segment further divides into API manufacturing and formulation teams, each with distinct tolerances for impurity profiles and packaging formats.

Source considerations separate fermentation-derived supply from synthetic origins, and buyers weigh trade-offs related to traceability, environmental footprint, and lot consistency. Production process segmentation differentiates biocatalysis from chemical synthesis, with biocatalytic routes offering superior stereoselectivity but sometimes requiring greater upstream process development. Form factors-liquid versus powder-impact logistics, storage, and formulation compatibility, while purity grade segmentation into high purity, standard, and ultra pure categories drives qualification burden, testing frequency, and price positioning. Collectively, these segmentation lenses inform supplier selection, validation timelines, and quality agreements, shaping how manufacturers prioritize investments in process capability and analytical control.

Regional strategic overview highlighting divergent sourcing priorities, regulatory expectations, and capability investments across major global territories

Regional patterns demonstrate differentiated strategic priorities and risk profiles across key geographies, and these differences materially influence how suppliers position capabilities and how buyers prioritize sourcing. In the Americas, commercial and regulatory trends favor nearshoring and integrated supply networks that reduce transit exposure and simplify regulatory filings, particularly for manufacturers focused on API manufacturing and formulation. Localized capacity expansions and investments in quality systems reflect an emphasis on secure supply and rapid responsiveness to clinical or commercial demand shifts.

In Europe, Middle East & Africa, regulatory rigor and sustainability expectations drive demand for transparent production processes, with purchasers placing a premium on documented impurity control and carbon-efficient pathways. Suppliers in this region often invest in high-quality analytical infrastructure and robust compliance frameworks to meet stringent standards. The Asia-Pacific region, as a major production and sourcing hub, balances high manufacturing scale with a growing focus on process modernization and environmental controls; buyers leverage Asia-Pacific capabilities for cost efficiency while increasingly demanding higher purity grades and certifications that align with global regulatory regimes. These regional dynamics underscore the importance of geographic diversification of supply, region-specific compliance strategies, and targeted investments to meet the nuanced requirements of each market cluster.

Organizational strategies and capability differentiators that create supplier advantage, including integration, analytics, partnerships, and quality leadership

Leading companies operating in this space exhibit distinct strategic archetypes that combine technical differentiation, quality assurance, and commercial agility. Some firms focus on deep vertical integration-linking raw material production to downstream API or formulation activities-to capture margin and control critical quality attributes, while others prioritize specialized high-purity manufacturing and premium positioning. Investment in advanced analytics, such as chiral purity assessment and impurity profiling, represents a common capability differentiator that facilitates faster customer qualification and reduces batch rejection risk.

Strategic partnerships between chemical manufacturers, biocatalysis specialists, and contract development and manufacturing organizations have become more frequent, enabling rapid route optimization and scale-up. Companies that successfully balance capacity scale with process flexibility-maintaining parallel synthetic and fermentation platforms-are better positioned to meet variable demand and regulatory expectations. Additionally, robust quality management systems and documented environmental health and safety practices increasingly serve as gatekeepers for preferred supplier status among pharmaceutical and agrochemical buyers. Overall, competitive advantage accrues to organizations that can demonstrably deliver consistent high-purity material, transparent supply chains, and responsive technical support during customer validation windows.

Actionable, cross-functional recommendations for reducing supply risk, accelerating process innovation, and aligning commercial terms with evolving trade and regulatory pressures

Industry leaders should adopt a multi-pronged set of actions that reduce supply risk, improve process efficiency, and strengthen customer relationships. First, diversify supplier portfolios across sources and regions to reduce exposure to trade policy shifts while actively qualifying suppliers that offer complementary production routes, including fermentation and synthetic capabilities. Second, invest in biocatalytic development and hybrid process adoption to achieve superior stereoselectivity and reduce downstream purification burdens, thereby improving overall yield and impurity control. These investments should be paired with enhanced analytical capability to rapidly characterize chiral purity and detect trace contaminants.

Third, align commercial contracts with evolving tariff landscapes by embedding flexible pricing and force-majeure clauses that recognize trade policy volatility, and by negotiating longer validation windows where supplier switching is anticipated. Fourth, prioritize sustainability initiatives that reduce solvent use, energy intensity, and waste streams, since these measures are increasingly linked to buyer preference and regulatory scrutiny. Finally, strengthen cross-functional collaboration among procurement, quality, and R&D to accelerate supplier qualification, optimize inventory strategies, and translate technical improvements into pricing and service advantages. Executed together, these actions will enhance resilience and enable growth in a more dynamic operating environment.

Description of the mixed-methods research approach combining expert interviews, technical literature synthesis, regulatory review, and scenario validation to ensure robust conclusions

The research underpinning this executive summary combines primary qualitative engagement with domain experts and secondary synthesis of publicly available technical literature, regulatory guidance, and patent landscapes to ensure a robust and balanced evidence base. Primary inputs included structured interviews with process chemists, quality leaders, procurement executives, and biocatalysis specialists, which provided direct insight into route selection trade-offs, qualification timelines, and purity requirements. Secondary sources informed the analysis of production technologies, regulatory expectations, and regional trade patterns, and were selected for technical rigor and relevance to synthesis and purity control.

To validate findings, cross-referencing occurred between interview data, technical white papers, and supplier disclosures where available, and scenario analysis explored the implications of tariff volatility, route substitution, and purity grade shifts. Data integrity measures included triangulation of claims across at least two independent sources and consultation with subject matter experts to reconcile divergent viewpoints. This mixed-methods approach delivered a comprehensive picture of technological trends, commercial pressures, and regulatory drivers while preserving practical orientation for decision makers responsible for procurement, process development, and strategic planning.

Concluding synthesis summarizing strategic imperatives around production route selection, supply resilience, quality control, and commercialization pathways

In conclusion, D-Alpha Parahydroxy Phenylglycine Methyl Ester is a strategically significant intermediate whose production route, purity grade, and geographic sourcing materially influence downstream development and commercial outcomes. The emergent landscape prioritizes process innovation-particularly biocatalysis and hybrid flows-alongside stronger analytical control and documented supply chain transparency. Tariff developments have heightened the premium on supplier diversification and contractual flexibility, incentivizing investments in regional capacity and process optimization to mitigate landed cost volatility and lead-time risk.

Companies that proactively invest in analytical capability, cross-train procurement and technical teams, and pursue targeted sustainability improvements will be better positioned to meet stringent regulatory expectations and buyer requirements. Collaboration between suppliers and end users to co-develop qualification protocols and impurity testing regimes also reduces time-to-market for new APIs and formulations. Ultimately, strategic focus on process selection, supply resilience, and quality assurance will determine which organizations convert this intermediate's technical importance into enduring competitive advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. D Alpha Parahydroxy Phenylglycine Methyl Ester Market, by Source

  • 8.1. Fermentation
  • 8.2. Synthetic

9. D Alpha Parahydroxy Phenylglycine Methyl Ester Market, by Production Process

  • 9.1. Biocatalysis
  • 9.2. Chemical Synthesis

10. D Alpha Parahydroxy Phenylglycine Methyl Ester Market, by Form

  • 10.1. Liquid
  • 10.2. Powder

11. D Alpha Parahydroxy Phenylglycine Methyl Ester Market, by Purity Grade

  • 11.1. High Purity
  • 11.2. Standard
  • 11.3. Ultra Pure

12. D Alpha Parahydroxy Phenylglycine Methyl Ester Market, by Application

  • 12.1. Antibiotics Intermediates
    • 12.1.1. Cephalosporin Class
    • 12.1.2. Penicillin Class
  • 12.2. Enzyme Inhibitors

13. D Alpha Parahydroxy Phenylglycine Methyl Ester Market, by End Use Industry

  • 13.1. Agrochemicals
  • 13.2. Personal Care
  • 13.3. Pharmaceuticals
    • 13.3.1. Api Manufacturing
    • 13.3.2. Formulation

14. D Alpha Parahydroxy Phenylglycine Methyl Ester Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. D Alpha Parahydroxy Phenylglycine Methyl Ester Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. D Alpha Parahydroxy Phenylglycine Methyl Ester Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States D Alpha Parahydroxy Phenylglycine Methyl Ester Market

18. China D Alpha Parahydroxy Phenylglycine Methyl Ester Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Ajinomoto Co., Inc.
  • 19.6. Amino GmbH
  • 19.7. BASF SE
  • 19.8. Cambrex Corporation
  • 19.9. Daicel Corporation
  • 19.10. Evonik Industries AG
  • 19.11. Hubei Xingfa Pharmaceuticals (Group) Co., Ltd
  • 19.12. Jiangsu Feiyue Pharmaceutical Co., Ltd.
  • 19.13. Jubilant Life Sciences Limited
  • 19.14. Lonza Group AG
  • 19.15. Mitsubishi Chemical Group Corporation
  • 19.16. Piramal Pharma Limited
  • 19.17. Shandong Lukang Pharmaceutical Co., Ltd.
  • 19.18. Shandong Xinhua Pharmaceutical Co., Ltd.
  • 19.19. Sichuan Guoguang Agrochemical Co., Ltd.
  • 19.20. Sichuan Tongsheng Amino Acid Co., Ltd.
  • 19.21. Sumitomo Chemical Co., Ltd.
  • 19.22. Taizhou Yuandong Biotechnology Co., Ltd.
  • 19.23. Thermo Fisher Scientific Inc.
  • 19.24. WuXi AppTec Co., Ltd
  • 19.25. Wuxi Jinghai Amino Acid Co., Ltd.
  • 19.26. Zhejiang Kaili Industrial Group Co., Ltd.
  • 19.27. Zhejiang NHU Co., Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FERMENTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FERMENTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FERMENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY BIOCATALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY BIOCATALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY BIOCATALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY CHEMICAL SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY CHEMICAL SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY HIGH PURITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY HIGH PURITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY HIGH PURITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY STANDARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY STANDARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY STANDARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ULTRA PURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ULTRA PURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ULTRA PURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY CEPHALOSPORIN CLASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY CEPHALOSPORIN CLASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY CEPHALOSPORIN CLASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PENICILLIN CLASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PENICILLIN CLASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PENICILLIN CLASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ENZYME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ENZYME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ENZYME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY AGROCHEMICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY AGROCHEMICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY AGROCHEMICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PERSONAL CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PERSONAL CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PERSONAL CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY API MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY API MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY API MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GCC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 149. GCC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 150. GCC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 151. GCC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 154. GCC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GCC D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 174. G7 D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. G7 D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 176. G7 D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 177. G7 D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 178. G7 D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. G7 D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 181. G7 D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 182. G7 D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 183. NATO D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. NATO D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 185. NATO D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 186. NATO D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 187. NATO D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. NATO D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 190. NATO D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 191. NATO D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY ANTIBIOTICS INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY END USE INDUSTRY, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA D ALPHA PARAHYDROXY PHENYLGLYCINE METHYL ESTER MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)